Colestipol (HCl)

Colestipol (HCl) is antihyperlipidimic agent. Chemically Colestipol (HCl) is a copolymer of diethylenetriamine and 1-chloro-2, 3-epoxypropane. Colestipol (HCl) is very large polymeric anion-exchange resins that is insoluble in water. Colestipol (HCl) is effective in reducing the high levels of cholesterol in blood.

Brands
Adult Dose
Dose: 71.429 to 214.285 mg/kg
Single Dose: 140 (142.857)
Frequency: 12 hourly
Route: PO
Instructions: -
Neonatal
Dose: Not recomended in this age group
Single Dose:
Frequency:
Route:
Instructions:
Paedriatic
Dose: 0.25 to 0.5 g/kg
Single Dose: 0.38 (0.375)
Frequency: 24 hourly
Route: Oral
Instructions: Increase 0.25g/kg every 2-3 Months
Characteristics
. It is of Natural origin and belongs to Resin. It belongs to Lipid lowering agents pharmacological group on the basis of mechanism of action. The Molecular Weight of Colestipol (HCl) is 318.29. It is weakly acidic drug.
Contraindications
Colestipol (HCl) is contraindicated in conditions like Intestinal obstruction,Diverticulitis,Anal fissure,Hernia.
Effects
The severe or irreversible adverse effects of Colestipol (HCl), which give rise to further complications include Constipation.The signs and symptoms that are produced after the acute overdosage of Colestipol (HCl) include Intestinal obstruction.The symptomatic adverse reactions produced by Colestipol (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Flatulence, Nausea, Vomiting, Diarrhea, Constipation, Heart burn, Abdominal discomfort.
Indications
Colestipol (HCl) is primarily indicated in conditions like Atherosclerosis, Bile salt-induced diarrhoea, Digitalis toxicity, Digitoxin toxication, Familial hypercholesterolaemia, Hypercholesterolaemia, Partial biliary obstruction-induced pruritus, Prophylaxis of NSAID-associated gastric or duodenal ulcer, Prophylaxis of NSAID-associated gastric or duodenal ulcer.
Interactions
Colestipol (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlfacalcidolit interferes with its actionAtorvastatinBendrofluazideBenzylpenicillin (Na or K)CalcifediolCalcitriolCerivastatin SodiumCerivastatin sodium has its effect moderately reduced by colestipolChenodeoxycholic AcidChlortetracycline (HCl)CholecalciferolDemeclocycline (HCl)Diclofenac (K)DigoxinColestipol may decrease the absorption of digoxin.ModerateMonitor for decreased serum concentrations/therapeutic effects of digoxin if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. Colestipol may be less likely to interact than cholestyramine. Frusemide or FurosemideColestipol may decrease the absorption of Furosemide. ModerateMonitor for decreased serum concentrations/therapeutic effects of Furosemide if coadministered with Colestipol. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction.GemfibrozilHydrochlorothiazideHydrocortisoneLoperamide (HCl)Metacycline (HCl)Minocycline (HCl)Nicotinic AcidPhenylbutazone Pravastatin (Na)ProbucolProbucolPropranolol (HCl)SimvastatinTetracycline (HCl)Tocopherol (Vitamin E)TorasemideColestipol and Colesevelam may decrease the bioavailability of Torasemide by inhibiting Torasemide absorption. Monitor for changes in the therapeutic and adverse effects of Torasemide if Colestipol is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction.Vitamin KWarfarin (Na) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Increased Values for LFTs
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tab Store at room temperature, Below 40°C. Protect from Sunlight and Moisture.
Warnings
Before starting therapy, investigate and treat diseases like diabetes mellitus, hypothyroidism, dysproteinemias or liver diseases. With long term therapy, supplemental vitamin A and D may be given. Periodically measure serum triglyceride level to detect significant changes. These agents may produced or severely worsen pre-existing constipation. A laxatives, stool softener or increased fluid intake may be helpful.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.